Efficacy of erlotinib in patients with relapsed gliobastoma multiforme who expressed EGFRVIII and PTEN determined by immunohistochemistry

Epidermal growth factor receptor gene (EGFR) alteration is a common feature in most of glioblastoma multiforme (GBM). Robust response of anti-EGFR treatments has been mostly associated with the EGFR deletion mutant variant III (EGFRvIII) and expression of PTEN. We have performed a prospective trial...

Descripción completa

Detalles Bibliográficos
Autores principales: Gallego, Oscar, Cuatrecasas, M., Benavides, M., Segura, P. P., Berrocal, A., Erill, N., Colomer, A., Quintana, M. J., Balaña, C., Gil, M., Gallardo, A., Murata, P., Barnadas, A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2013
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3890043/
https://www.ncbi.nlm.nih.gov/pubmed/24352766
http://dx.doi.org/10.1007/s11060-013-1316-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3890043/
https://www.ncbi.nlm.nih.gov/pubmed/24352766
http://dx.doi.org/10.1007/s11060-013-1316-y

Ejemplares similares